Developer docs
API playgroundTry for free, no card

Search company profiles

Renovia

Full company profile

uuid0002gfx

Namestring
Renovia
Legal namestring
Axena Health, Inc.
Websiteurl
renoviainc.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Renovia was a developer of prescription digital therapeutics for pelvic floor disorders, founded in 2016 and headquartered in Boston, Massachusetts. Its core product, the Leva Pelvic Health System, is a non-invasive, non-drug digital therapeutic device that delivers pelvic floor muscle training to treat urinary incontinence (including overactive bladder symptoms of urgency, frequency, and leakage) and fecal incontinence in women. The product is supported by randomized controlled trials and real-world evidence studies published in Urogynecology, and is positioned as a clinically-proven alternative to medication or surgery. The company targets two primary segments: women with pelvic health conditions, accessed via clinicians and a consumer site (LevaCares.com), and female veterans reached through federal healthcare channels including the Veterans Health Administration and VA Community Care.

The business raised approximately $72.3M across a 2017 round, a 2018 Series B (~$32.3M, led by Ascension Ventures and Perceptive Advisors), 2018 and 2020 venture debt tranches, and a 2021 Series C ($17.0M, led by Parian Global Management). Renovia ceased operations in late 2022; the Leva product line and operating activity have continued through Axena Health, Inc. (founded 2021 in Massachusetts), led by CEO and Chief Medical Officer Samantha Pulliam and VP of Consumer and Commercial Operations Annette Brewster. Under Axena, the company has expanded internationally with a Nigerian urinary incontinence feasibility study presented at FIGO 2025, joined the AgeTech Collaborative from AARP accelerator targeting women 50+, and added fecal incontinence clinical evidence via a 2026 RCT and real-world study, while maintaining a headcount of 11-50 employees and a federal procurement channel via the VHA.

Pricing is not publicly disclosed; the model is a prescription digital therapeutic sold through federal healthcare procurement and, presumably, clinical and consumer channels, with patient education and awareness marketing concentrated on LevaCares.com. The combination of a single regulated product, a small commercial team, concentrated federal distribution, and ongoing clinical evidence publications characterizes an early commercial-stage women's health Dtx business.

Short descriptiontext

Renovia developed the Leva Pelvic Health System, a non-invasive, prescription digital therapeutic for women with urinary and fecal incontinence, distributed via clinicians, the LevaCares.com consumer site, and the Veterans Health Administration. Following a 2022 wind-down, the product line continues through Axena Health.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
digital therapeutics, pelvic floor rehabilitation, women's health devices, urinary incontinence treatment, fecal incontinence therapy
Industry3 codes
PRIMARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAO
DTx/SaMD Deployment, Integration & Reimbursement Enablement
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAK
Women’s Health & Fertility Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Home Health Equipment Rental532283
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Digital Pelvic Health Therapeutics
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Leva Pelvic Health System
Description

Non-drug, non-surgical pelvic health treatment system shown to improve bladder leakage in just 4 weeks.

axenahealth.com
Core offering1 text field

Renovia (operating through Axena Health, Inc.) develops the Leva Pelvic Health System, a prescription digital therapeutic device for women's pelvic floor rehabilitation. The system is a non-invasive, non-drug, non-surgical solution used to treat bladder leakage (including overactive bladder symptoms such as urgency, frequency, and leakage) and fecal incontinence. The product combines a sensor-based training device with educational content and a connected digital platform, supported by randomized controlled trials and real-world evidence.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Improves bladder leakage symptoms in just 4 weeks
Product overview1 text field

Axena Health offers the Leva Pelvic Health System, a single clinically proven non-invasive digital therapeutic product for women's pelvic health. The system provides digital pelvic floor rehabilitation therapy as a non-drug, non-surgical solution to treat urinary incontinence (bladder leakage) and fecal incontinence, backed by randomized controlled trials and real-world evidence studies published in Urogynecology.

Product and service1 record
1Leva Pelvic Health System
CategoryDigital Therapeutics / Medical Device
Description

A non-drug, non-surgical digital therapeutic device for women's pelvic health that provides pelvic floor rehabilitation therapy to treat bladder leakage (including overactive bladder symptoms such as leakage, urgency, frequency) and fecal incontinence. Includes enhanced educational content and is clinically proven with peer-reviewed research backing its efficacy. Targeted at women with pelvic floor disorders and female veterans receiving care through the Veterans Health Administration.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Carrot provides a global fertility and reproductive health benefits platform. Comparable as a women's health employer/benefits channel that increasingly covers pelvic and continence care, making it a potential distribution partner or adjacent competitor.

2Pelvital
TypeDirect peer
Description

Pelvital's Flyte device delivers mechanotherapy for stress urinary incontinence via a prescribed at-home device, closely mirroring Leva's prescription-positioned, clinically-validated pelvic floor therapy approach. Strong direct peer on clinical positioning, prescriber channel, and female incontinence indication.

3Elvie
TypeDirect peer
Description

Elvie sells consumer-facing connected pelvic floor trainers (e.g., Elvie Trainer) targeted at postpartum and incontinence use, the same core category as the Leva Pelvic Health System. Direct overlap in product mechanism (biofeedback-based pelvic floor exercise device) and target customer (women with stress/urinary incontinence).

TypeBroad incumbent
Description

Tia operates women's health clinics combined with a digital care platform, addressing many of the same clinical conditions (urinary incontinence, pelvic floor concerns) as Axena. Comparable as a women's health brand and care-delivery model, though Tia owns in-person clinical infrastructure.

TypeBroad incumbent
Description

Hologic is a major women's health medical device and diagnostics company with deep relationships in urogynecology and pelvic floor surgical markets. Comparable as a broad incumbent whose installed base of urogynecologists could accelerate or block adoption of Leva as a non-surgical alternative.

TypeDirect peer
Description

Perifit offers app-connected Kegel trainers for pelvic floor strengthening, directly competing with Leva on the consumer side. Comparable product form factor, business model (hardware + subscription content), and target demographic of women experiencing urinary incontinence.

TypeEmerging player
Description

Hyivy Health is developing a connected pelvic health rehabilitation device with clinical-grade outcomes tracking. Emerging peer in the same condition-specific DTx / device category as Leva, with partial overlap on pelvic floor disorders and digital measurement.

TypeBroad incumbent
Description

BD's urology and continence care portfolio (catheters, continence products) overlaps with the downstream care pathway for women treated via Leva. Comparable as a broad incumbent across female continence/urological care with significant commercial reach.

TypeDirect peer
Description

Atlantic Therapeutics markets INNOVO, an FDA-cleared neuromuscular electrical stimulation garment for stress urinary incontinence, competing head-to-head with Leva on mechanism, indication, and prescriber channel. Direct peer in prescription-grade pelvic floor therapy devices.

TypeBroad incumbent
Description

Maven Clinic is a large digital women's health platform spanning fertility, maternity, postpartum, and menopause. While broader than Leva's narrow pelvic-floor focus, it competes for the same female-payer/employer wallet and represents a potential channel partner or competitor for women's pelvic health services.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Renovia

Digital Pelvic Health Therapeuticsrenoviainc.com

Renovia developed the Leva Pelvic Health System, a non-invasive, prescription digital therapeutic for women with urinary and fecal incontinence, distributed via clinicians, the LevaCares.com consumer site, and the Veterans Health Administration. Following a 2022 wind-down, the product line continues through Axena Health.

What Renovia does

Renovia was a developer of prescription digital therapeutics for pelvic floor disorders, founded in 2016 and headquartered in Boston, Massachusetts. Its core product, the Leva Pelvic Health System, is a non-invasive, non-drug digital therapeutic device that delivers pelvic floor muscle training to treat urinary incontinence (including overactive bladder symptoms of urgency, frequency, and leakage) and fecal incontinence in women. The product is supported by randomized controlled trials and real-world evidence studies published in Urogynecology, and is positioned as a clinically-proven alternative to medication or surgery. The company targets two primary segments: women with pelvic health conditions, accessed via clinicians and a consumer site (LevaCares.com), and female veterans reached through federal healthcare channels including the Veterans Health Administration and VA Community Care.

The business raised approximately $72.3M across a 2017 round, a 2018 Series B (~$32.3M, led by Ascension Ventures and Perceptive Advisors), 2018 and 2020 venture debt tranches, and a 2021 Series C ($17.0M, led by Parian Global Management). Renovia ceased operations in late 2022; the Leva product line and operating activity have continued through Axena Health, Inc. (founded 2021 in Massachusetts), led by CEO and Chief Medical Officer Samantha Pulliam and VP of Consumer and Commercial Operations Annette Brewster. Under Axena, the company has expanded internationally with a Nigerian urinary incontinence feasibility study presented at FIGO 2025, joined the AgeTech Collaborative from AARP accelerator targeting women 50+, and added fecal incontinence clinical evidence via a 2026 RCT and real-world study, while maintaining a headcount of 11-50 employees and a federal procurement channel via the VHA.

Pricing is not publicly disclosed; the model is a prescription digital therapeutic sold through federal healthcare procurement and, presumably, clinical and consumer channels, with patient education and awareness marketing concentrated on LevaCares.com. The combination of a single regulated product, a small commercial team, concentrated federal distribution, and ongoing clinical evidence publications characterizes an early commercial-stage women's health Dtx business.

Renovia firmographics

Firmographics
Name
Renovia
Legal name
Axena Health, Inc.
Website
https://renoviainc.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Renovia developed the Leva Pelvic Health System, a non-invasive, prescription digital therapeutic for women with urinary and fecal incontinence, distributed via clinicians, the LevaCares.com consumer site, and the Veterans Health Administration. Following a 2022 wind-down, the product line continues through Axena Health.
Ownership category
akta.pro rank

Renovia industry classification

Industry
Product category
Digital Pelvic Health Therapeutics
NAICS
Home Health Equipment Rental (532283)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACANAA
Condition-specific Digital Therapeutics (DTx)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAO
DTx/SaMD Deployment, Integration & Reimbursement Enablement
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAK
Women’s Health & Fertility Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Digital therapeutics
  • Pelvic floor rehabilitation
  • Women's health devices
  • Urinary incontinence treatment
  • Fecal incontinence therapy

Where Renovia is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Renovia business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Distribution channels1 record

Marketing channels1 record

Renovia product offering

Product offering

Core offering

Renovia (operating through Axena Health, Inc.) develops the Leva Pelvic Health System, a prescription digital therapeutic device for women's pelvic floor rehabilitation. The system is a non-invasive, non-drug, non-surgical solution used to treat bladder leakage (including overactive bladder symptoms such as urgency, frequency, and leakage) and fecal incontinence. The product combines a sensor-based training device with educational content and a connected digital platform, supported by randomized controlled trials and real-world evidence.

Product overview

Axena Health offers the Leva Pelvic Health System, a single clinically proven non-invasive digital therapeutic product for women's pelvic health. The system provides digital pelvic floor rehabilitation therapy as a non-drug, non-surgical solution to treat urinary incontinence (bladder leakage) and fecal incontinence, backed by randomized controlled trials and real-world evidence studies published in Urogynecology.

Differentiator

Problem solved

Functional benefit

Brands

  • Leva Pelvic Health System: Non-drug, non-surgical pelvic health treatment system shown to improve bladder leakage in just 4 weeks.

Products and services

  • Leva Pelvic Health System A non-drug, non-surgical digital therapeutic device for women's pelvic health that provides pelvic floor rehabilitation therapy to treat bladder leakage (including overactive bladder symptoms such as leakage, urgency, frequency) and fecal incontinence. Includes enhanced educational content and is clinically proven with peer-reviewed research backing its efficacy. Targeted at women with pelvic floor disorders and female veterans receiving care through the Veterans Health Administration.

Quantifiable outcome

  • Improves bladder leakage symptoms in just 4 weeks

Companies that use Renovia

Customer profile

Segments2 records

Ideal customer profiles2 records

Renovia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Renovia partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights5 records

Renovia competitors and assessment

Company assessment

Broad incumbents

  • Carrot Fertility: Carrot provides a global fertility and reproductive health benefits platform. Comparable as a women's health employer/benefits channel that increasingly covers pelvic and continence care, making it a potential distribution partner or adjacent competitor.
  • Tia: Tia operates women's health clinics combined with a digital care platform, addressing many of the same clinical conditions (urinary incontinence, pelvic floor concerns) as Axena. Comparable as a women's health brand and care-delivery model, though Tia owns in-person clinical infrastructure.
  • Hologic: Hologic is a major women's health medical device and diagnostics company with deep relationships in urogynecology and pelvic floor surgical markets. Comparable as a broad incumbent whose installed base of urogynecologists could accelerate or block adoption of Leva as a non-surgical alternative.
  • BD (Becton Dickinson): BD's urology and continence care portfolio (catheters, continence products) overlaps with the downstream care pathway for women treated via Leva. Comparable as a broad incumbent across female continence/urological care with significant commercial reach.
  • Maven Clinic: Maven Clinic is a large digital women's health platform spanning fertility, maternity, postpartum, and menopause. While broader than Leva's narrow pelvic-floor focus, it competes for the same female-payer/employer wallet and represents a potential channel partner or competitor for women's pelvic health services.

Direct peers

  • Pelvital: Pelvital's Flyte device delivers mechanotherapy for stress urinary incontinence via a prescribed at-home device, closely mirroring Leva's prescription-positioned, clinically-validated pelvic floor therapy approach. Strong direct peer on clinical positioning, prescriber channel, and female incontinence indication.
  • Elvie: Elvie sells consumer-facing connected pelvic floor trainers (e.g., Elvie Trainer) targeted at postpartum and incontinence use, the same core category as the Leva Pelvic Health System. Direct overlap in product mechanism (biofeedback-based pelvic floor exercise device) and target customer (women with stress/urinary incontinence).
  • Perifit: Perifit offers app-connected Kegel trainers for pelvic floor strengthening, directly competing with Leva on the consumer side. Comparable product form factor, business model (hardware + subscription content), and target demographic of women experiencing urinary incontinence.
  • Atlantic Therapeutics: Atlantic Therapeutics markets INNOVO, an FDA-cleared neuromuscular electrical stimulation garment for stress urinary incontinence, competing head-to-head with Leva on mechanism, indication, and prescriber channel. Direct peer in prescription-grade pelvic floor therapy devices.

Emerging players

  • Hyivy Health: Hyivy Health is developing a connected pelvic health rehabilitation device with clinical-grade outcomes tracking. Emerging peer in the same condition-specific DTx / device category as Leva, with partial overlap on pelvic floor disorders and digital measurement.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Renovia social profiles

Digital presence

Renovia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Renovia leadership team

Management profile

Number of profiles

Profiles2 records

Renovia funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Renovia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Renovia

What does Renovia do?

Renovia (operating through Axena Health, Inc.) develops the Leva Pelvic Health System, a prescription digital therapeutic device for women's pelvic floor rehabilitation. The system is a non-invasive, non-drug, non-surgical solution used to treat bladder leakage (including overactive bladder symptoms such as urgency, frequency, and leakage) and fecal incontinence. The product combines a sensor-based training device with educational content and a connected digital platform, supported by randomized controlled trials and real-world evidence.

Is Renovia a public or private company?

Renovia is a private company. It is classified as venture growth investor backed and is currently operating.

When was Renovia founded?

Renovia was founded in 2021. It employs 1 to 10 people.

Where is Renovia based?

Renovia is headquartered in Boston, United States, in the North America region.

Who are Renovia's main competitors?

Broad incumbents on record are Carrot Fertility, Tia, Hologic, BD (Becton Dickinson) and Maven Clinic. Direct peers are Pelvital, Elvie, Perifit and Atlantic Therapeutics. Hyivy Health is listed as an emerging player.

Does Renovia have an API?

No public API is recorded for Renovia.

What industry is Renovia in?

Renovia's product category is Digital Pelvic Health Therapeutics. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of HLACANAO, DTx/SaMD Deployment, Integration & Reimbursement Enablement. Its NAICS code is 532283 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ObviohealthThe First-Ever Fully Virtual Clinical Trial in UrogynecologyObvioHealth and Renovia conducted the first fully virtual clinical trial in urogynecology to assess an at-home medical device for treating urinary incontinence. The trial successfully enrolled 350 patients in 14 weeks, achieving a retention rate of 89% and lower recruitment costs of $67 per patient. This innovative approach was necessitated by the pandemic, enabling the participation of older female patients who were hesitant to attend in-person visits.PR NewswirePublished studies find low documented adherence to guideline-based care for female urinary incontinenceTwo studies published in Neurourology and Urodynamics found that less than 8% of women with stress or mixed urinary incontinence received documented first-line behavioral treatments such as pelvic floor muscle training, while less than 3% visited a physical therapist for UI treatment. Researchers discovered that women who did not receive guideline-adherent care accrued significantly higher healthcare costs for payers over a two-year period following diagnosis. The studies were commissioned by Renovia Inc., whose FDA-cleared leva Pelvic Health System is positioned as a digital therapeutic solution to improve adherence to pelvic floor muscle training protocols.MPRFDA Clears Prescription Digital Therapeutic for Women With Fecal IncontinenceThe Food and Drug Administration (FDA) has cleared Renovia Inc.'s leva® Pelvic Health System for first-line treatment of chronic fecal incontinence in women, expanding the device's previous approval which covered stress, mixed, and mild to moderate urge incontinence. The clearance was based on a 10-week pilot study of 29 women showing significant improvement in fecal incontinence symptoms and quality of life among the 27 women with evaluable data. Renovia's CEO stated that the clearance represents an opportunity to treat a condition that has been underreported due to social stigma, with the system offering discreet, at-home, nonsurgical, drug-free symptom relief via a vaginal wand with motion sensors paired to a mobile app.PR NewswireRenovia receives FDA clearance for leva® Pelvic Health System as first-line treatment for chronic fecal incontinenceRenovia Inc. announced that the U.S. Food and Drug Administration has cleared its leva® Pelvic Health System for the first-line treatment of chronic fecal incontinence in women, following a Breakthrough Device Designation granted in October 2021. The prescription digital therapeutic combines a vaginal motion sensor with a smartphone app to guide pelvic floor muscle training, offering a non-invasive, drug-free treatment option for the over 12 million U.S. women affected by the condition. The FDA clearance expands the device's previous indication, which covered stress, mixed and mild-to-moderate urinary incontinence in women.PR NewswirePublished health economics study shows improved treatment for female urinary incontinence may have positive effect on patient outcomes and healthcare costsRenovia Inc. announced a peer-reviewed study published in Neurourology and Urodynamics showing that women with stress or mixed urinary incontinence incur significantly higher medical costs and resource utilization for US payers compared to those without the condition. The research indicated a 61% increase in total costs over two years, concluding that enhanced evaluation and treatment of urinary incontinence could reduce overall medical expenses and improve patient health outcomes.MassgeneralPromising Digital Therapeutic Device for Pelvic Floor Muscle TrainingA multicenter randomized controlled trial evaluated Renovia Inc.'s FDA-cleared leva Pelvic Health System, a motion-based digital biofeedback device for pelvic floor muscle training, comparing it against conventional Kegel exercises in 77 women with stress urinary incontinence. The trial found no significant difference in co-primary outcomes between the device group and control group, but secondary outcomes showed the device group achieved significantly fewer incontinence episodes and greater improvements on symptom-specific quality of life measures. A subsequent fully powered randomized trial validated these findings, confirming greater improvement in urinary symptom severity with the digital therapeutic device compared to unaided pelvic floor muscle training.PR NewswireRenovia debuts "Stronger Women" campaign at annual gathering of women's health care leadersRenovia Inc. launched its "Stronger Women" brand campaign at the ACOG Annual Clinical & Scientific Meeting in San Diego on May 6, 2022, to educate clinicians and women about urinary incontinence and promote the leva Pelvic Health System. A randomized controlled study published in Obstetrics and Gynecology in April 2022 demonstrated that leva users experienced significant improvement in UI symptoms, with leakage episodes decreasing from nearly two per day to one every three days. The campaign seeks to make first-line treatment for UI more accessible and reduce the stigma surrounding the condition.PR NewswireFirst infographic guiding treatment pathway for female urinary incontinence publishes in Journal of Women's HealthRenovia Inc. announced the publication of a first-of-its-kind infographic in the Journal of Women's Health that provides a visual shared decision-making tool synthesizing evidence-based guidelines for female urinary incontinence screening, evaluation, and treatment. The infographic, developed by Renovia's medical team, addresses a significant treatment gap as moderate to more severe UI affects over 28 million women in the U.S. yet fewer than 25% seek care. The tool aims to increase access to first-line treatment such as pelvic floor muscle training by packaging clinical guidelines in an easy-to-access graphical format for frontline clinicians.PR NewswirePrestigious journal shows leva Pelvic Health System significantly improves urinary incontinence symptoms in womenA study published in the journal Obstetrics & Gynecology on March 10 found that women with urinary incontinence who used Renovia Inc.'s leva Pelvic Health System combined with pelvic floor muscle training achieved significantly greater symptom improvement compared to those performing Kegel exercises alone. The leva system uses motion sensor technology paired with a smartphone app and personal coaching to help women perform pelvic floor exercises correctly. The National Association for Continence highlighted the study as offering a new treatment option for the estimated 78 million women affected by urinary incontinence.